T2MR Technology

T2 Magnetic Resonance (T2MR®) – The technology platform for next-generation diagnostics

T2MR, a diagnostic detection method utilizing miniaturized magnetic resonance technology, measures how water molecules react in the presence of magnetic fields. Over 200 studies published in peer-reviewed journals have featured T2MR in a breadth of applications including the direct detection and measurement of such targets as whole blood, plasma, serum, saliva, sputum and urine. The T2MR technology platform offers a fast, simple and sensitive alternative to existing diagnostic methodologies.  

T2MR technology powers all of the diagnostic innovation at T2 Biosystems and enables the detection of a variety of different targets including:

  • Molecular targets – e.g., DNA, pathogen cells.
  • Immunodiagnostics – e.g., proteins.
  • A broad range of hemostasis measurements.

T2MR and nanotechnology

To detect diagnostic targets, T2MR utilizes advances in the field of nanotechnology. Specifically, T2MR technology:

  • Deploys particles with superparamagnetic properties that enhance the magnetic resonance signals of specific binding events. 
  • When particles coated with target-specific binding agents are added to a sample containing the target, the particles bind to and cluster around the target. 
  • This clustering changes the microscopic environment of water molecules in that sample, which, in turn, alters the magnetic resonance signal, or the T2 relaxation signal measured, indicating the presence, absence or concentration of the target.

Direct detection from sample

Unlike all other detection methods, T2MR is the first detection technology that can quickly and accurately identify molecular targets within patient samples without the need for purification or extraction of target molecules from the sample. T2MR technology can eliminate these time- and labor-intensive steps because the T2 relaxation signal is not compromised or disrupted by the sample background, even for the highly complex sample background present in blood from patients suspected of having sepsis. 

For example, this allows T2MR to detect targets directly from whole blood, without blood culture. This differs entirely from diagnostic systems that rely on traditional polymerase chain reaction (PCR) in which purification and extraction are required, causing 90% of the target to be lost.1 Due to these sensitivity limitations, these systems require time-consuming and insensitive blood culturing in order for them to detect at the low levels required for the pathogens associated with sepsis.

Low limits of detection and high sensitivity

T2MR technology enables the T2Dx Instrument and T2Candida® Panel’s exquisite sensitivity—as low as 1 CFU/mL—compared to the 100 to 1,000 CFU/mL required by PCR-based in vitro diagnostics. In addition: 

  • In a peer-reviewed publication, the T2Candida Panel demonstrated 99.4% specificity and 91.1% sensitivity.2 
  • T2MR performs equally as well in the presence of antimicrobial therapy, which has been shown to inhibit blood culture sensitivity.

T2MR in hemostasis

For hemostasis measurements, particles are not required because T2MR is highly sensitive to changes in the microenvironment of a blood sample, such as clot formation, contraction and lysis, which alter the T2 relaxation signal. This allows for the rapid identification of clinically relevant hemostasis changes. 

T2MR in other applications

We believe the potential applications for T2MR extend within and outside of the in vitro diagnostics market, including environmental, food safety, industrial and veterinary applications.

Learn more about the impact T2MR is having on patient care and hospital economics

The T2Dx Instrument and T2Candida Panel have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only

……………………………………….
1. PLoS ONE | www.plosone.org | October 2010 | Volume 5 | Issue 10 | e13387 
2. 
1. Mylonakis, E., Clancy, C.J., Ostrosky-Zeichner, et. al. (2015). T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. Clinical infectious diseases, ciu959.